Wanbury Limited has informed the Exchange regarding Board meeting held on August 04, 2025.
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Wanbury Limited announced its Q1 FY26 (ended June 30, 2025) unaudited financial results. Standalone revenue from operations rose to Rs. 16,318.40 lakhs from Rs. 13,110.82 lakhs in Q1 FY25, a growth of about 24%. Profit after tax jumped sharply to Rs. 1,349.05 lakhs from Rs. 103.74 lakhs in the same quarter last year, with basic EPS improving to Rs. 4.12 from Rs. 0.32. The board also approved the grant of 91,500 stock options to employees under the Wanbury ESOP 2016 at Rs. 10 per option, and noted the allotment of 1,06,500 equity shares on exercise of previously vested options. Mr. Chandran Krishnamoorthy was re-appointed as Whole-time Director for 5 years from September 18, 2025, subject to shareholder approval. The board also initiated closure of three non-operational foreign subsidiaries in the Netherlands, China, and UAE, which never commenced business and will not impact revenue.
Strong topline growth of about 24% and a dramatic surge in profit signal a sharp operational turnaround versus the weak Q1 FY25 base. The clean (unmodified) auditor review and closure of inactive subsidiaries are routine housekeeping moves. The big jump in PAT is partly a low-base effect, so investors should track consistency in coming quarters before assuming a sustained earnings upgrade.